trending Market Intelligence /marketintelligence/en/news-insights/trending/47crzrqvhpxpqzd2hmoboa2 content esgSubNav
In This List

Sanofi closes $11.6B Bioverativ buy

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sanofi closes $11.6B Bioverativ buy

France's Sanofi completed the $11.6 billion acquisition of hemophilia drugmaker Bioverativ Inc.

The pharmaceuticals giant's tender offer to acquire all outstanding shares of Bioverativ for $105 apiece expired as scheduled on time.

Bioverativ will operate as a subsidiary of Sanofi and its common stock will cease to be traded on the Nasdaq.